+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID06964737

Phase I Study of Anti-GARP CAR T Cell Therapy Delivered into the Brain Cavity for Recurrent Grade III or IV Gliomas

Led by Ohio State University Comprehensive Cancer Center · Updated on 2026-05-08

30

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a new treatment called anti-GARP chimeric antigen receptor CAR T cell therapy for patients with recurrent grade III or IV gliomas, which are high-grade brain tumors that have returned after initial improvement. This phase I trial aims to assess the safety, side effects, and best dose of this therapy. CAR T-cell therapy involves modifying a patients immune cells to better attack tumor cells. The study also plans to explore how the therapy affects the immune response and tumor activity over time, including survival outcomes and tumor marker expression. Participants undergo a series of procedures starting with apheresis to collect their T cells, followed by surgery to place a cerebrospinal fluid CSF reservoir. The modified anti-GARP CAR T cells are then infused directly into the brain cavity on days 14, 21, 28, 35, and 42 if the disease does not progress or unacceptable side effects occur. Throughout the study, patients receive various scans and tests such as echocardiography or MUGA, chest x-rays, MRI scans, lumbar punctures, and blood and CSF sample collections to monitor safety and treatment effects. During the trial, participants will be closely monitored for dose-limiting toxicities up to 30 days after the first dose. Adverse events, immune cell characteristics, cytokine levels, tumor responses by imaging, progression-free and overall survival will be tracked for up to 15 years. Follow-up visits occur frequently in the first months and then annually for at least 15 years. This long-term monitoring helps researchers understand the therapys lasting effects and safety.

CONDITIONS

Brief Title

Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas

Research Team

O

Ohio State University Comprehensive Cancer Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here